1. Home
  2. CRSP vs GXO Comparison

CRSP vs GXO Comparison

Compare CRSP & GXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GXO
  • Stock Information
  • Founded
  • CRSP 2013
  • GXO 2021
  • Country
  • CRSP Switzerland
  • GXO United States
  • Employees
  • CRSP N/A
  • GXO N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GXO Transportation Services
  • Sector
  • CRSP Health Care
  • GXO Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • GXO Nasdaq
  • Market Cap
  • CRSP 4.2B
  • GXO 4.8B
  • IPO Year
  • CRSP 2016
  • GXO N/A
  • Fundamental
  • Price
  • CRSP $59.12
  • GXO $50.53
  • Analyst Decision
  • CRSP Buy
  • GXO Buy
  • Analyst Count
  • CRSP 16
  • GXO 13
  • Target Price
  • CRSP $71.20
  • GXO $55.69
  • AVG Volume (30 Days)
  • CRSP 3.5M
  • GXO 1.7M
  • Earning Date
  • CRSP 08-04-2025
  • GXO 08-05-2025
  • Dividend Yield
  • CRSP N/A
  • GXO N/A
  • EPS Growth
  • CRSP N/A
  • GXO N/A
  • EPS
  • CRSP N/A
  • GXO 0.62
  • Revenue
  • CRSP $37,675,000.00
  • GXO $12,230,000,000.00
  • Revenue This Year
  • CRSP $30.25
  • GXO $9.65
  • Revenue Next Year
  • CRSP $268.62
  • GXO $5.97
  • P/E Ratio
  • CRSP N/A
  • GXO $80.44
  • Revenue Growth
  • CRSP N/A
  • GXO 23.40
  • 52 Week Low
  • CRSP $30.04
  • GXO $30.46
  • 52 Week High
  • CRSP $63.68
  • GXO $63.33
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 83.65
  • GXO 71.49
  • Support Level
  • CRSP $50.26
  • GXO $49.70
  • Resistance Level
  • CRSP $53.08
  • GXO $51.21
  • Average True Range (ATR)
  • CRSP 2.78
  • GXO 1.41
  • MACD
  • CRSP 0.93
  • GXO 0.14
  • Stochastic Oscillator
  • CRSP 98.13
  • GXO 95.23

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GXO GXO Logistics Inc.

GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.

Share on Social Networks: